Drug Trial Radar · NCT06312644
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Dec 16, 2024
Primary completion
Jul 11, 2034
Study completion Jul 11, 2034
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
Conditions
- Ultomiris-exposed Pregnant/ Postpartum
- Pregnancy
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Generalized Myasthenia Gravis (gMG)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
UltomirisDrug
Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pregnancy ComplicationsTime frame: Up to 4 weeks post-delivery
- Maternal ComplicationsTime frame: Up to 4 weeks post-delivery
- Fetal/Infant OutcomesTime frame: In utero through 52 weeks of age after exposure to Ultomiris (in utero or via breastmilk)
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Boston, Massachusetts · Recruiting
Research Site
Melbourne, Victoria, Australia · Not yet recruiting
Research Site
Paris, France · Recruiting
Research Site
Essen, Norte-Westfalia, Germany · Recruiting
Research Site
Rome, Italy · Recruiting
Research Site
Seoul, South Korea · Active not recruiting
Research Site
London, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.